169 related articles for article (PubMed ID: 18539537)
1. Early identification of interferon-beta responders by ex vivo testing in patients with multiple sclerosis.
Wiesemann E; Deb M; Hemmer B; Radeke HH; Windhagen A
Clin Immunol; 2008 Sep; 128(3):306-13. PubMed ID: 18539537
[TBL] [Abstract][Full Text] [Related]
2. Effects of interferon-beta on co-signaling molecules: upregulation of CD40, CD86 and PD-L2 on monocytes in relation to clinical response to interferon-beta treatment in patients with multiple sclerosis.
Wiesemann E; Deb M; Trebst C; Hemmer B; Stangel M; Windhagen A
Mult Scler; 2008 Mar; 14(2):166-76. PubMed ID: 17942524
[TBL] [Abstract][Full Text] [Related]
3. Interferon-beta up-regulates the expression of co-stimulatory molecules CD80, CD86 and CD40 on monocytes: significance for treatment of multiple sclerosis.
Marckmann S; Wiesemann E; Hilse R; Trebst C; Stangel M; Windhagen A
Clin Exp Immunol; 2004 Dec; 138(3):499-506. PubMed ID: 15544628
[TBL] [Abstract][Full Text] [Related]
4. The interleukin-10 levels as a potential indicator of positive response to interferon beta treatment of multiple sclerosis patients.
Bartosik-Psujek H; Stelmasiak Z
Clin Neurol Neurosurg; 2006 Oct; 108(7):644-7. PubMed ID: 16343740
[TBL] [Abstract][Full Text] [Related]
5. Interferon-beta enhances monocyte and dendritic cell expression of B7-H1 (PD-L1), a strong inhibitor of autologous T-cell activation: relevance for the immune modulatory effect in multiple sclerosis.
Schreiner B; Mitsdoerffer M; Kieseier BC; Chen L; Hartung HP; Weller M; Wiendl H
J Neuroimmunol; 2004 Oct; 155(1-2):172-82. PubMed ID: 15342209
[TBL] [Abstract][Full Text] [Related]
6. Short-term treatment of relapsing remitting multiple sclerosis patients with interferon (IFN)-beta1B transiently increases the blood levels of interleukin (IL)-6, IL-10 and IFN-gamma without significantly modifying those of IL-1beta, IL-2, IL-4 and tumour necrosis factor-alpha.
Nicoletti F; Di Marco R; Patti F; Zaccone P; L'Episcopo MR; Reggio E; Xiang M; Nicoletti A; Reggio A
Cytokine; 2000 Jun; 12(6):682-7. PubMed ID: 10843745
[TBL] [Abstract][Full Text] [Related]
7. Long-term favorable response to interferon beta-1b is linked to cytokine deviation toward the Th2 and Tc2 sides in Japanese patients with multiple sclerosis.
Mei FJ; Osoegawa M; Ochi H; Minohara M; Nan S; Murai H; Ishizu T; Taniwaki T; Kira J
J Neurol Sci; 2006 Jul; 246(1-2):71-7. PubMed ID: 16581087
[TBL] [Abstract][Full Text] [Related]
8. Time-dependent cytokine deviation toward the Th2 side in Japanese multiple sclerosis patients with interferon beta-1b.
Ochi H; Feng-Jun M; Osoegawa M; Minohara M; Murai H; Taniwaki T; Kira J
J Neurol Sci; 2004 Jul; 222(1-2):65-73. PubMed ID: 15240198
[TBL] [Abstract][Full Text] [Related]
9. Monocyte-derived HLA-G acts as a strong inhibitor of autologous CD4 T cell activation and is upregulated by interferon-beta in vitro and in vivo: rationale for the therapy of multiple sclerosis.
Mitsdoerffer M; Schreiner B; Kieseier BC; Neuhaus O; Dichgans J; Hartung HP; Weller M; Wiendl H
J Neuroimmunol; 2005 Feb; 159(1-2):155-64. PubMed ID: 15652415
[TBL] [Abstract][Full Text] [Related]
10. Interleukin-10 and interleukin-12 modulation in patients with relapsing-remitting multiple sclerosis on therapy with interferon-beta 1a: differences in responders and non responders.
Carrieri PB; Ladogana P; Di Spigna G; de Leva MF; Petracca M; Montella S; Buonavolontà L; Florio C; Postiglione L
Immunopharmacol Immunotoxicol; 2008; 30(4):1-9. PubMed ID: 18686100
[TBL] [Abstract][Full Text] [Related]
11. Could cytokines levels or adhesion molecules expression be predictor of IFN-beta treatment response in multiple sclerosis patients?
Sega S; Horvat A; Rot U; Wraber B; Ihan A
Clin Neurol Neurosurg; 2008 Nov; 110(9):947-50. PubMed ID: 18396372
[TBL] [Abstract][Full Text] [Related]
12. Beneficial effect of interferon-beta 1b treatment in patients with relapsing-remitting multiple sclerosis is associated with an increase in serum levels of soluble HLA-I molecules during the first 3 months of therapy.
Fainardi E; Rizzo R; Melchiorri L; Castellazzi M; Govoni V; Caniatti L; Paolino E; Tola MR; Granieri E; Baricordi OR
J Neuroimmunol; 2004 Mar; 148(1-2):206-11. PubMed ID: 14975603
[TBL] [Abstract][Full Text] [Related]
13. Interleukin-1 receptor antagonist, soluble tumor necrosis factor-alpha receptor type I and II, and soluble E-selectin serum levels in multiple sclerosis patients receiving weekly intramuscular injections of interferon-beta1a.
Perini P; Tiberio M; Sivieri S; Facchinetti A; Biasi G; Gallo P
Eur Cytokine Netw; 2000 Mar; 11(1):81-6. PubMed ID: 10705303
[TBL] [Abstract][Full Text] [Related]
14. Interferon-beta regulates cytokines and BDNF: greater effect in relapsing than in progressive multiple sclerosis.
Hamamcioglu K; Reder AT
Mult Scler; 2007 May; 13(4):459-70. PubMed ID: 17463069
[TBL] [Abstract][Full Text] [Related]
15. Expression of Th1 and Th17 cytokines and transcription factors in multiple sclerosis patients: does baseline T-bet mRNA predict the response to interferon-beta treatment?
Drulovic J; Savic E; Pekmezovic T; Mesaros S; Stojsavljevic N; Dujmovic-Basuroski I; Kostic J; Vasic V; Mostarica Stojkovic M; Popadic D
J Neuroimmunol; 2009 Oct; 215(1-2):90-5. PubMed ID: 19695714
[TBL] [Abstract][Full Text] [Related]
16. Increased IL-10 mRNA and IL-23 mRNA expression in multiple sclerosis: interferon-beta treatment increases IL-10 mRNA expression while reducing IL-23 mRNA expression.
Krakauer M; Sorensen P; Khademi M; Olsson T; Sellebjerg F
Mult Scler; 2008 Jun; 14(5):622-30. PubMed ID: 18424480
[TBL] [Abstract][Full Text] [Related]
17. Synergistic immunomodulatory effects of interferon-beta1b and the phosphodiesterase inhibitor pentoxifylline in patients with relapsing-remitting multiple sclerosis.
Weber F; Polak T; Günther A; Kubuschok B; Janovskaja J; Bitsch A; Poser S; Rieckmann P
Ann Neurol; 1998 Jul; 44(1):27-34. PubMed ID: 9667590
[TBL] [Abstract][Full Text] [Related]
18. The effect of beta-interferon therapy on myelin basic protein-elicited CD4+ T cell proliferation and cytokine production in multiple sclerosis.
Hedegaard CJ; Krakauer M; Bendtzen K; Sørensen PS; Sellebjerg F; Nielsen CH
Clin Immunol; 2008 Oct; 129(1):80-9. PubMed ID: 18653385
[TBL] [Abstract][Full Text] [Related]
19. [T-cell interferon-gamma, tumor necrosis factor-alpha and interleukin-6 receptor binding in patients with multiple sclerosis. Effects of interferon-beta-1b treatment].
Bongioanni P; Romano MR; Boccardi B; Lombardo F; Moscato G; Mosti S; Baldini C; Nuti S; Meucci G; Rossi B
Rev Neurol; 1999 Nov 16-30; 29(10):893-9. PubMed ID: 10637835
[TBL] [Abstract][Full Text] [Related]
20. Interferon-beta therapy up-regulates BDNF secretion from PBMCs of MS patients through a CD40-dependent mechanism.
Azoulay D; Mausner-Fainberg K; Urshansky N; Fahoum F; Karni A
J Neuroimmunol; 2009 Jun; 211(1-2):114-9. PubMed ID: 19419774
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
